Sifei Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sifei Wang has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Shuling Liu
Huanhu Hospital Affiliated to Tianjin Medical University, Tianjin Medical University, China (Y.X., Shuling Liu, X. Jiang, Shuai Liu, K.D., X.Q., X.T., M.W.).
4 shared publications - Leilei Luo
Department of Neurology, Tianjin Huanhu Hospital, Tianjin, China
3 shared publications - Ming Wei
Department of Neurosurgery, Tianjin Huanhu Hospital, China (M.W.).
3 shared publications - Xunming Ji
Capital Medical University
3 shared publications - Yongbo Xu
Huanhu Hospital Affiliated to Tianjin Medical University, Tianjin Medical University, Tianjin, China
3 shared publications - Jiayue Ding
Department of Neurology, Tianjin Medical University General Hospital, China (J.D.).
2 shared publications
Latest Publications
- 1 September 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (9) , 2631-2642
Ischemic Postconditioning in Patients With Acute Stroke With Successful Recanalization After Endovascular Therapy: A Pilot Randomized Controlled Trial
BACKGROUND: Ischemia-reperfusion injury contributes to continued infarct growth despite successful recanalization. Ischemic postconditioning (IPostC) reduces infarct size in preclinical models, but its therapeutic effect as an adjunct to endovascular thrombectomy remains uncertain. We investigated whether IPostC performed after successful recanalization reduces infarct growth in patients with acute ischemic stroke. METHODS: This single-center, prospective, randomized, open-label trial with blinded end point assessment was conducted at Tianjin Huanhu Hospital between September 2024 and May 2025. Patients with acute ischemic stroke who underwent endovascular thrombectomy within 24 hours of symptom onset or last known well, had a baseline National Institutes of Health Stroke Scale score ≥6 and a prestroke modified Rankin Scale score ≤2, and achieved successful recanalization after endovascular thrombectomy were randomly assigned to the IPostC or control group. IPostC consisted of 4 cycles of 2-minute balloon inflation followed by 2-minute deflation, with the balloon positioned at the original intracranial arterial occlusion site. The primary outcome was infarct growth from baseline to 48-hour magnetic resonance imaging (MRI). Secondary outcomes included infarct volume on immediate postprocedure MRI (within 2 hours) and on 48-hour MRI; early infarct growth and late infarct growth; serial National Institutes of Health Stroke Scale scores during hospitalization; and modified Rankin Scale score at 90 days. Primary and secondary outcomes were analyzed in the intention-to-treat population using unadjusted between-group comparisons. RESULTS: Sixty patients were enrolled, with 30 randomly assigned to each group. Infarct growth from baseline to 48-hour MRI was lower with IPostC than with control (median difference, −8.7 mL [95% CI, −17.1 to −1.4]; P =0.015). In the serial MRI subgroup (n=30; 15 per group), early infarct growth was also lower with IPostC (median difference, −3.2 mL [95% CI, −8.7 to −0.1]; P =0.045). Patients in the IPostC group had a lower National Institutes of Health Stroke Scale score at 24 hours (median difference, −3.0 [95% CI, −5.0 to −1.0]; P =0.005). The 90-day modified Rankin Scale distribution did not differ significantly between groups (common odds ratio, 1.1 [95% CI, 0.4–2.6]; P =0.921). CONCLUSIONS: In this pilot randomized trial, IPostC performed after successful recanalization reduced infarct growth in patients with acute ischemic stroke due to large-vessel occlusion. These findings require confirmation in larger randomized trials. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06545734.
- 1 September 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (9) , 2631-2642
Ischemic Postconditioning in Patients With Acute Stroke With Successful Recanalization After Endovascular Therapy: A Pilot Randomized Controlled Trial
BACKGROUND: Ischemia-reperfusion injury contributes to continued infarct growth despite successful recanalization. Ischemic postconditioning (IPostC) reduces infarct size in preclinical models, but its therapeutic effect as an adjunct to endovascular thrombectomy remains uncertain. We investigated whether IPostC performed after successful recanalization reduces infarct growth in patients with acute ischemic stroke. METHODS: This single-center, prospective, randomized, open-label trial with blinded end point assessment was conducted at Tianjin Huanhu Hospital between September 2024 and May 2025. Patients with acute ischemic stroke who underwent endovascular thrombectomy within 24 hours of symptom onset or last known well, had a baseline National Institutes of Health Stroke Scale score ≥6 and a prestroke modified Rankin Scale score ≤2, and achieved successful recanalization after endovascular thrombectomy were randomly assigned to the IPostC or control group. IPostC consisted of 4 cycles of 2-minute balloon inflation followed by 2-minute deflation, with the balloon positioned at the original intracranial arterial occlusion site. The primary outcome was infarct growth from baseline to 48-hour magnetic resonance imaging (MRI). Secondary outcomes included infarct volume on immediate postprocedure MRI (within 2 hours) and on 48-hour MRI; early infarct growth and late infarct growth; serial National Institutes of Health Stroke Scale scores during hospitalization; and modified Rankin Scale score at 90 days. Primary and secondary outcomes were analyzed in the intention-to-treat population using unadjusted between-group comparisons. RESULTS: Sixty patients were enrolled, with 30 randomly assigned to each group. Infarct growth from baseline to 48-hour MRI was lower with IPostC than with control (median difference, −8.7 mL [95% CI, −17.1 to −1.4]; P =0.015). In the serial MRI subgroup (n=30; 15 per group), early infarct growth was also lower with IPostC (median difference, −3.2 mL [95% CI, −8.7 to −0.1]; P =0.045). Patients in the IPostC group had a lower National Institutes of Health Stroke Scale score at 24 hours (median difference, −3.0 [95% CI, −5.0 to −1.0]; P =0.005). The 90-day modified Rankin Scale distribution did not differ significantly between groups (common odds ratio, 1.1 [95% CI, 0.4–2.6]; P =0.921). CONCLUSIONS: In this pilot randomized trial, IPostC performed after successful recanalization reduced infarct growth in patients with acute ischemic stroke due to large-vessel occlusion. These findings require confirmation in larger randomized trials. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06545734.
- 1 August 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (8) , 2265-2275
Adjunctive Normobaric Hyperoxia With Endovascular Thrombectomy for Acute Stroke at 6 to 24 Hours: A Phase IIb Randomized Trial
BACKGROUND: Normobaric hyperoxia (NBO) is a simple neuroprotective strategy that may augment endovascular thrombectomy (EVT) in acute ischemic stroke. We evaluated the safety and preliminary efficacy of NBO plus EVT in patients with large-vessel occlusion presenting 6 to 24 hours after onset. METHODS: In this phase IIb, randomized, assessor-blinded, controlled trial conducted at 2 academic comprehensive stroke centers in China, patients aged ≥18 years with anterior circulation large-vessel occlusion presenting 6 to 24 hours after acute ischemic stroke onset were assigned 1:1 to EVT+NBO or EVT alone. The NBO group received 100% oxygen via a face mask at 10 L/min for 4 hours, starting before recanalization. The primary end point was early neurological improvement (≥30% reduction in the National Institutes of Health Stroke Scale score at 24 hours). Primary analyses used adjusted regression models controlling for prespecified prognostic covariates. Secondary end points included infarct volume at 24 to 48 hours and the modified Rankin Scale score at 90 days. Safety outcomes were mortality, intracranial hemorrhage, and symptomatic intracranial hemorrhage. Analyses followed the intention-to-treat principle. Early neurological improvement was analyzed using an adjusted binomial regression model, and the 90-day modified Rankin Scale shift was analyzed using an adjusted ordinal logistic regression model, controlling for age, sex, intravenous thrombolysis, and occlusion site. RESULTS: Between October 2021 and October 2023, 324 patients were screened, and 120 were randomly assigned to NBO+EVT or EVT alone (60 patients per group; intention-to-treat population). The median baseline National Institutes of Health Stroke Scale score was 12 (interquartile range [IQR], 8–15) in the NBO+EVT group and 12 (IQR, 9–16) in the EVT-alone group. The median time from stroke onset to randomization was 10.0 hours (IQR, 7.0–14.4) and 9.9 hours (IQR, 8.4–14.8), respectively. The EVT+NBO group demonstrated a significantly higher rate of early neurological improvement compared with EVT alone (35% versus 19%; adjusted odds ratio, 2.86 [95% CI, 1.12–7.45]). The median infarct volume at 24 to 48 hours was significantly smaller in the EVT+NBO group (20.5 [IQR, 13.6–31.8] mL versus 32.3 [IQR, 22.7–44.5] mL; P =0.001). At 90 days, the modified Rankin Scale distribution numerically favored NBO+EVT but was not statistically significant (median modified Rankin Scale, 2 [IQR, 1–3] versus 3 [IQR, 1–4]; adjusted common odds ratio, 1.52 [95% CI, 0.87–2.63]). Mortality, symptomatic intracranial hemorrhage, early neurological deterioration, and recurrent stroke did not differ between groups. CONCLUSIONS: In patients with acute ischemic stroke treated 6 to 24 hours after onset, adjunctive NBO with EVT was safe and improved early neurological outcomes and infarct volume, supporting further evaluation in larger trials. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05128422.
- 1 August 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (8) , 2265-2275
Adjunctive Normobaric Hyperoxia With Endovascular Thrombectomy for Acute Stroke at 6 to 24 Hours: A Phase IIb Randomized Trial
BACKGROUND: Normobaric hyperoxia (NBO) is a simple neuroprotective strategy that may augment endovascular thrombectomy (EVT) in acute ischemic stroke. We evaluated the safety and preliminary efficacy of NBO plus EVT in patients with large-vessel occlusion presenting 6 to 24 hours after onset. METHODS: In this phase IIb, randomized, assessor-blinded, controlled trial conducted at 2 academic comprehensive stroke centers in China, patients aged ≥18 years with anterior circulation large-vessel occlusion presenting 6 to 24 hours after acute ischemic stroke onset were assigned 1:1 to EVT+NBO or EVT alone. The NBO group received 100% oxygen via a face mask at 10 L/min for 4 hours, starting before recanalization. The primary end point was early neurological improvement (≥30% reduction in the National Institutes of Health Stroke Scale score at 24 hours). Primary analyses used adjusted regression models controlling for prespecified prognostic covariates. Secondary end points included infarct volume at 24 to 48 hours and the modified Rankin Scale score at 90 days. Safety outcomes were mortality, intracranial hemorrhage, and symptomatic intracranial hemorrhage. Analyses followed the intention-to-treat principle. Early neurological improvement was analyzed using an adjusted binomial regression model, and the 90-day modified Rankin Scale shift was analyzed using an adjusted ordinal logistic regression model, controlling for age, sex, intravenous thrombolysis, and occlusion site. RESULTS: Between October 2021 and October 2023, 324 patients were screened, and 120 were randomly assigned to NBO+EVT or EVT alone (60 patients per group; intention-to-treat population). The median baseline National Institutes of Health Stroke Scale score was 12 (interquartile range [IQR], 8–15) in the NBO+EVT group and 12 (IQR, 9–16) in the EVT-alone group. The median time from stroke onset to randomization was 10.0 hours (IQR, 7.0–14.4) and 9.9 hours (IQR, 8.4–14.8), respectively. The EVT+NBO group demonstrated a significantly higher rate of early neurological improvement compared with EVT alone (35% versus 19%; adjusted odds ratio, 2.86 [95% CI, 1.12–7.45]). The median infarct volume at 24 to 48 hours was significantly smaller in the EVT+NBO group (20.5 [IQR, 13.6–31.8] mL versus 32.3 [IQR, 22.7–44.5] mL; P =0.001). At 90 days, the modified Rankin Scale distribution numerically favored NBO+EVT but was not statistically significant (median modified Rankin Scale, 2 [IQR, 1–3] versus 3 [IQR, 1–4]; adjusted common odds ratio, 1.52 [95% CI, 0.87–2.63]). Mortality, symptomatic intracranial hemorrhage, early neurological deterioration, and recurrent stroke did not differ between groups. CONCLUSIONS: In patients with acute ischemic stroke treated 6 to 24 hours after onset, adjunctive NBO with EVT was safe and improved early neurological outcomes and infarct volume, supporting further evaluation in larger trials. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05128422.
- 24 December 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (12) , 2263-2270
Intra-arterial albumin following endovascular reperfusion for large vessel occlusion stroke: a prospective cohort study
Background: Preclinical reports suggest that intra-arterial (IA) 20% albumin may have neuroprotective effects. A 3+3 dose-escalation pilot clinical trial preliminarily confirmed the safety and feasibility of doses up to 0.6 g/kg. Based on these findings, we aimed to evaluate the safety and explore the potential efficacy of adjunctive IA albumin in acute ischemic stroke patients undergoing endovascular thrombectomy (EVT). Methods: This prospective single-center cohort trial enrolled patients with successful recanalization (defined as a score on the expanded Thrombolysis In Cerebral Infarction (eTICI) scale of 2b to 3). Patients were classified into the EVT alone group and IA albumin group. The primary endpoint was any intracranial hemorrhage (ICH). Secondary endpoints included pulmonary edema/congestive heart failure, symptomatic ICH, and all-cause mortality within 90 days. Exploratory efficacy endpoints included excellent outcome at 90 days (defined as a modified Rankin Scale score of 0–1), final infarct volume, and glymphatic system activity quantified by diffusion tensor imaging via the ALPS (analysis along the perivascular space) index. Results: We enrolled 251 patients, with 103 in the IA albumin group and 148 in the EVT alone group. After propensity score matching, each group had 103 patients with balanced baseline characteristics. The primary safety outcome of any ICH occurred in 16.5% of the albumin group versus 25.2% of controls, with no statistically significant difference between groups (OR 0.25, 95% CI 0.25 to 1.09, P=0.081). No significant differences were observed in other safety outcomes. In the post hoc exploratory efficacy analyses, the IA albumin group had a greater likelihood of excellent neurological outcome at 90 days, smaller final infarct volumes, and higher ALPS index. Conclusion: In patients with acute large vessel occlusion, adjunctive IA albumin after successful thrombectomy was safe and well-tolerated. In post hoc exploratory analyses, this treatment was associated with a higher likelihood of achieving an excellent neurological outcome at 90 days and with reduced final infarct volume. The neuroprotective effect may be mediated by restoration of glymphatic function. These promising findings warrant validation in multicenter randomized trials.
- 24 December 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (12) , 2263-2270
Intra-arterial albumin following endovascular reperfusion for large vessel occlusion stroke: a prospective cohort study
Background: Preclinical reports suggest that intra-arterial (IA) 20% albumin may have neuroprotective effects. A 3+3 dose-escalation pilot clinical trial preliminarily confirmed the safety and feasibility of doses up to 0.6 g/kg. Based on these findings, we aimed to evaluate the safety and explore the potential efficacy of adjunctive IA albumin in acute ischemic stroke patients undergoing endovascular thrombectomy (EVT). Methods: This prospective single-center cohort trial enrolled patients with successful recanalization (defined as a score on the expanded Thrombolysis In Cerebral Infarction (eTICI) scale of 2b to 3). Patients were classified into the EVT alone group and IA albumin group. The primary endpoint was any intracranial hemorrhage (ICH). Secondary endpoints included pulmonary edema/congestive heart failure, symptomatic ICH, and all-cause mortality within 90 days. Exploratory efficacy endpoints included excellent outcome at 90 days (defined as a modified Rankin Scale score of 0–1), final infarct volume, and glymphatic system activity quantified by diffusion tensor imaging via the ALPS (analysis along the perivascular space) index. Results: We enrolled 251 patients, with 103 in the IA albumin group and 148 in the EVT alone group. After propensity score matching, each group had 103 patients with balanced baseline characteristics. The primary safety outcome of any ICH occurred in 16.5% of the albumin group versus 25.2% of controls, with no statistically significant difference between groups (OR 0.25, 95% CI 0.25 to 1.09, P=0.081). No significant differences were observed in other safety outcomes. In the post hoc exploratory efficacy analyses, the IA albumin group had a greater likelihood of excellent neurological outcome at 90 days, smaller final infarct volumes, and higher ALPS index. Conclusion: In patients with acute large vessel occlusion, adjunctive IA albumin after successful thrombectomy was safe and well-tolerated. In post hoc exploratory analyses, this treatment was associated with a higher likelihood of achieving an excellent neurological outcome at 90 days and with reduced final infarct volume. The neuroprotective effect may be mediated by restoration of glymphatic function. These promising findings warrant validation in multicenter randomized trials.
- 8 September 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (9) , 1842-1848
Intra-arterial human serum albumin therapy following mechanical thrombectomy for acute ischemic stroke: the AMASS pilot trial
Background Despite successful mechanical thrombectomy (MT), approximately 50% of patients with large vessel occlusion (LVO) stroke experience poor outcomes due to reperfusion injury. Intra-arterial infusion of human serum albumin (HSA) may offer neuroprotective benefits; however, its safety and feasibility have not been established when delivered via the internal carotid artery. In this study we aimed to evaluate the safety and technical feasibility of HSA infusion through the guiding catheter placed during MT in patients with anterior circulation LVO stroke following successful reperfusion. Methods We conducted a prospective, single-center, open-label, pilot trial evaluating intra-arterial infusion of 20% HSA immediately after MT in patients with anterior circulation LVO stroke. The study included a 3+3 dose-escalation and a dose-expansion phase. Eligible patients achieved successful reperfusion (modified Thrombolysis in Cerebral Infarction score ≥2b) and received HSA infusion via the guiding catheter. Safety endpoints included 90-day mortality, symptomatic intracranial hemorrhage (sICH), and serious adverse events. Post-hoc analyses explored infarct volume, immune markers, and proteomic/metabolomic signatures. Results Between September 2023 and February 2024, 42 patients received intra-arterial HSA infusion. In the dose-escalation phase (n=27), two deaths and two mild infusion-related adverse events occurred, with no sICH. In the dose-expansion phase (n=15), one death and one case of sICH were reported, with no HSA-related adverse events. Post-hoc analysis showed that the HSA group had a significantly smaller infarct volume at 24 hours compared with controls. Conclusions Intra-arterial infusion of 20% HSA in combination with MT is safe and feasible. Preliminary findings suggest a potential therapeutic benefit in reducing infarct volume. Trial registration number NCT05953623.
- 8 September 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (9) , 1842-1848
Intra-arterial human serum albumin therapy following mechanical thrombectomy for acute ischemic stroke: the AMASS pilot trial
Background Despite successful mechanical thrombectomy (MT), approximately 50% of patients with large vessel occlusion (LVO) stroke experience poor outcomes due to reperfusion injury. Intra-arterial infusion of human serum albumin (HSA) may offer neuroprotective benefits; however, its safety and feasibility have not been established when delivered via the internal carotid artery. In this study we aimed to evaluate the safety and technical feasibility of HSA infusion through the guiding catheter placed during MT in patients with anterior circulation LVO stroke following successful reperfusion. Methods We conducted a prospective, single-center, open-label, pilot trial evaluating intra-arterial infusion of 20% HSA immediately after MT in patients with anterior circulation LVO stroke. The study included a 3+3 dose-escalation and a dose-expansion phase. Eligible patients achieved successful reperfusion (modified Thrombolysis in Cerebral Infarction score ≥2b) and received HSA infusion via the guiding catheter. Safety endpoints included 90-day mortality, symptomatic intracranial hemorrhage (sICH), and serious adverse events. Post-hoc analyses explored infarct volume, immune markers, and proteomic/metabolomic signatures. Results Between September 2023 and February 2024, 42 patients received intra-arterial HSA infusion. In the dose-escalation phase (n=27), two deaths and two mild infusion-related adverse events occurred, with no sICH. In the dose-expansion phase (n=15), one death and one case of sICH were reported, with no HSA-related adverse events. Post-hoc analysis showed that the HSA group had a significantly smaller infarct volume at 24 hours compared with controls. Conclusions Intra-arterial infusion of 20% HSA in combination with MT is safe and feasible. Preliminary findings suggest a potential therapeutic benefit in reducing infarct volume. Trial registration number NCT05953623.
- 1 June 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (6) , 1468-1476
Normobaric Hyperoxia Combined With Endovascular Treatment Based on Temporal Gradient: A Dose-Escalation Study
BACKGROUND: Normobaric hyperoxia (NBO) has neuroprotective effects in acute ischemic stroke. Thus, we aimed to identify the optimal NBO treatment duration combined with endovascular treatment. METHODS: This is a single-center, randomized controlled, open-label, blinded-end point dose-escalation clinical trial. Patients with acute ischemic stroke who had an indication for endovascular treatment at Tianjin Huanhu Hospital were randomly assigned to 4 groups (1:1 ratio) based on NBO therapy duration: (1) control group (1 L/min oxygen for 4 hours); (2) NBO-2h group (10 L/min for 2 hours); (3) NBO-4h group (10 L/min for 4 hours); and (4) NBO-6h group (10 L/min for 6 hours). The primary outcome was cerebral infarction volume at 72 hours after randomization using an intention-to-treat analysis model. The primary safety outcome was the 90-day mortality rate. RESULTS: Between June 2022 and September 2023, 100 patients were randomly assigned to the following groups: control group (n=25), NBO-2h group (n=25), NBO-4h group (n=25), and NBO-6h group (n=25). The 72-hour cerebral infarct volumes were 39.4±34.3 mL, 30.6±30.1 mL, 19.7±15.4 mL, and 22.6±22.4 mL, respectively ( P =0.013). The NBO-4h and NBO-6h groups both showed statistically significant differences (adjusted P values: 0.011 and 0.027, respectively) compared with the control group. Compared with the control group, both the NBO-4h and NBO-6h groups showed significant differences ( P <0.05) in the National Institutes of Health Stroke Scale scores at 24 hours, 72 hours, and 7 days, as well as in the change of the National Institutes of Health Stroke Scale scores from baseline to 24 hours. Additionally, there were no significant differences among the 4 groups in terms of 90-day mortality rate, symptomatic intracranial hemorrhage, early neurological deterioration, or severe adverse events. CONCLUSIONS: The effectiveness of NBO therapy was associated with oxygen administration duration. Among patients with acute ischemic stroke who underwent endovascular treatment, NBO therapy for 4 and 6 hours was found to be more effective. Larger-scale multicenter studies are needed to validate these findings. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05404373.
- 1 June 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (6) , 1468-1476
Normobaric Hyperoxia Combined With Endovascular Treatment Based on Temporal Gradient: A Dose-Escalation Study
BACKGROUND: Normobaric hyperoxia (NBO) has neuroprotective effects in acute ischemic stroke. Thus, we aimed to identify the optimal NBO treatment duration combined with endovascular treatment. METHODS: This is a single-center, randomized controlled, open-label, blinded-end point dose-escalation clinical trial. Patients with acute ischemic stroke who had an indication for endovascular treatment at Tianjin Huanhu Hospital were randomly assigned to 4 groups (1:1 ratio) based on NBO therapy duration: (1) control group (1 L/min oxygen for 4 hours); (2) NBO-2h group (10 L/min for 2 hours); (3) NBO-4h group (10 L/min for 4 hours); and (4) NBO-6h group (10 L/min for 6 hours). The primary outcome was cerebral infarction volume at 72 hours after randomization using an intention-to-treat analysis model. The primary safety outcome was the 90-day mortality rate. RESULTS: Between June 2022 and September 2023, 100 patients were randomly assigned to the following groups: control group (n=25), NBO-2h group (n=25), NBO-4h group (n=25), and NBO-6h group (n=25). The 72-hour cerebral infarct volumes were 39.4±34.3 mL, 30.6±30.1 mL, 19.7±15.4 mL, and 22.6±22.4 mL, respectively ( P =0.013). The NBO-4h and NBO-6h groups both showed statistically significant differences (adjusted P values: 0.011 and 0.027, respectively) compared with the control group. Compared with the control group, both the NBO-4h and NBO-6h groups showed significant differences ( P <0.05) in the National Institutes of Health Stroke Scale scores at 24 hours, 72 hours, and 7 days, as well as in the change of the National Institutes of Health Stroke Scale scores from baseline to 24 hours. Additionally, there were no significant differences among the 4 groups in terms of 90-day mortality rate, symptomatic intracranial hemorrhage, early neurological deterioration, or severe adverse events. CONCLUSIONS: The effectiveness of NBO therapy was associated with oxygen administration duration. Among patients with acute ischemic stroke who underwent endovascular treatment, NBO therapy for 4 and 6 hours was found to be more effective. Larger-scale multicenter studies are needed to validate these findings. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05404373.